7. Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit.
8. Patients who required treatment with non-permitted concomitant therapies.
9. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, electrocardiogram results, and physical examination, that would have placed the patient at risk upon exposure to the study medication or that may have confounded the analysis and/or interpretation of the study results.
10. Active alcohol or drug abuse.
11. Patients suffering from giant cell arteritis, late-onset rheumatoid arthritis or other inflammatory rheumatoid diseases. The protocol was amended to exclude patients who had pre-study documented evidence of raised rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) from study entry.
12. Patients suffering from drug-induced myalgia.
13. Patients suffering from fibromyalgia.
14. Patients suffering from systemic lupus erythemathosus.
15. Patients suffering from neurological conditions, e.g. Parkinson's disease.
16. Patients suffering from active cancer.
17. Patients suffering from an active infection. In France, patients who were at risk of infection were also excluded.
18. Patients who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days prior to the Screening Visit.
The following exclusion criteria were added for France only:
19. Patients suffering from non-controlled diabetes.
20. Patients suffering from non-controlled hypertension.
21. Patients suffering from ophthalmological problems (glaucoma, ulceration, etc.).
Patients who had had tuberculosis.

Randomisation and Blinding
Randomisation was performed using an interactive response technology system and used blocking methodology via a country-based randomisation method (stratified for country). The patient and all personnel involved with the conduct and interpretation of the study were blinded to the medication codes.
Matching placebo tablets for MR prednisone and IR prednisone were used to maintain the blind. Patients randomised to IR prednisone took 15mg IR prednisone in the morning between 5am and 9am and took matching placebo for MR prednisone in the evening at 10pm ± 30 minutes. Patients randomised to MR prednisone took matching placebo for IR prednisone in the morning between 5am and 9am and 15mg MR prednisone in the evening at 10pm ± 30 minutes. Patients were instructed to take the evening dose of MR prednisone/placebo with a light meal or snack. 
Quality of Life Assessments
Statistical Methods
The primary endpoint was analysed using logistic regression with treatment as a factor and baseline PMR VAS score, baseline duration of morning stiffness, and baseline (screening) CRP as covariates. Difference estimators based on the logistic regression model were calculated with accompanying standard error for the difference calculated by the delta method. [3] Non-inferiority was to be concluded if the lower limit of the two-sided 95% confidence interval (CI) was greater than or equal to -15%. The non-inferiority margin was based on clinically important treatment differences, as well as considering ethical and regulatory criteria, cost, and feasibility. It was assumed that the complete response rate with the comparator, IR prednisone, would be 30% higher than for placebo, thus to ensure that MR prednisone preserved at least half of the effect of IR prednisone, [2] the non-inferiority margin was set at -15%. The primary analysis was conducted using a modified last observation carried forward (mLOCF) approach to handle missing data.
For most secondary endpoints, changes from baseline were analysed using repeated measures analysis of covariance, including treatment (and visit, where appropriate) as factors and baseline value as a covariate. Change from baseline in duration of morning stiffness was analysed using the Hodges Lehmann method for median treatment differences, using LOCF. Response endpoints were analysed using logistic regression models, including treatment as a factor, and baseline score as a covariate, using a mLOCF approach. The statistical models were used to calculate the treatment difference/odds ratio, the corresponding 95% CI, and the p-value. The EQ-5D index score, HAQ-DI score and HAQ-DI response rate were summarised descriptively. For EQ-5D, the conversion between the ordinal scores to an index was performed using the UK Time Trade Off preference weights. [3] All secondary efficacy endpoints were analysed using the FAP.
Safety presentations were descriptive and based on the safety population (all randomised patients who received at least one dose of study treatment). Adverse events were coded using MedDRA version 16. Statistical programming and analyses were performed using SAS ® version 9.1.3 or higher (SAS Institute, Cary, North Carolina, USA).
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Reasons for exclusion of patients from the PPP were: taking excluded concomitant medication (6 patients), violation of inclusion/exclusion criteria (4 patients), <80% compliance with study treatment (3 patients), missing values for primary endpoint (2 patients) and error in treatment assignment (1 patient). 
Open-label Extension Phase
Protocol Amendments
There were five amendments to the original protocol (dated 23 August 2012); including one global amendment and four local amendments. All amendments, except protocol amendment 5, were implemented before recruitment of subjects into the study.
Protocol amendment 1 (08 January 2013) was a local amendment (UK only) that amended the inclusion criteria for the extension phase to clarify that subjects with active infection were not eligible for entry into the open-label extension phase of the study.
Protocol amendment 2 (30 January 2013) was a global amendment that reflected the change in the duration of morning stiffness indicating that patients can be classified as having PMR to >45 minutes according to the EULAR/ACR 2012 Provisional Classification Criteria for PMR. The amendment also required the measurement of RF and ACPA. Elevated results for these tests indicated that a subject had underlying rheumatoid arthritis (RA). Underlying RA would have excluded the subject from the PPP.
Protocol amendment 3 (30 January 2013) was a local amendment (France only) that, in response to French Ethics Committee questions, clarified diagnosis time for PMR and added to the inclusion criteria that subjects could not be under legal protection or in the judicial system.
Protocol amendment 4 (01 February 2013) was a local amendment (Germany only) that, in response to German Ethics Committee questions, added to the inclusion criteria that subjects could not be under legal protection or in the judicial system, added that vital signs were to be recorded at each visit, and added that the Declaration of Helsinki Revision 4 (1996) would also be followed.
Protocol amendment 5 (25 July 2013) was a local amendment (France only), which added the following exclusion criteria and also included ophthalmological surveillance in the study in response to French Competent Authority questions:
 Subjects suffering from an active infection or who were at risk of infection;  Subjects with non-controlled diabetes;  Subjects with non-controlled hypertension;  Subjects with ophthalmological problems (glaucoma, ulceration, etc.);
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 Subjects with a history of tuberculosis.
Quality of Life Results
For Blood and lymphatic system disorders 3 (9.4) 0 1 (9.1) 1 (6. 
